Selumetinib

Independent reference data for Selumetinib (CAS 606143-52-6), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Selumetinib is indicated for the treatment of neurofibromatosis type 1 (NF1) in adult and pediatric patients one year of age and older who have symptomatic, inoperable plexiform neurofibromas (PN).Selumetinib is an oral, small molecule inhibitor of the mitogen activated protein kinase 1 and 2 (MEK1/2) that is used to treat symptomatic, refractory fibromas in neurofibromatosis type 1. Selumetinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has not been linked to cases of clinically apparent acute liver injury.

Synonyms and trade names

Selumetinib; 606143-52-6; AZD6244; ARRY-142886; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD 6244; AZD-6244; ARRY-886; selumetinibum; DTXSID3048944; 6UH91I579U; ARRY142886; DTXCID0028870; CHEBI:90227; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-

GHS hazard classification

Reported hazard statements	H302 (40%), H317 (80%), H318 (60%), H361 (80%), H373 (80%), H411 (60%), H413 (20%)

H302 (40%): Harmful if swallowed [Warning Acute toxicity, oral]

H317 (80%): May cause an allergic skin reaction [Warning Sensitization, Skin]

What the public record says

Selumetinib · CAS 606143-52-6 · C17H15BrClFN4O3. UNII 6UH91I579U.

Source: PubChem / Wikidata; the batch COA governs where values differ.